Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
08 04 2021
Historique:
received: 22 04 2020
accepted: 15 09 2020
pubmed: 10 10 2020
medline: 13 10 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

Chronic lymphocytic leukemia (CLL) major stereotyped subset 2 (IGHV3-21/IGLV3-21, ∼2.5% of all cases of CLL) is an aggressive disease variant, irrespective of the somatic hypermutation (SHM) status of the clonotypic IGHV gene. Minor stereotyped subset 169 (IGHV3-48/IGLV3-21, ∼0.2% of all cases of CLL) is related to subset 2, as it displays a highly similar variable antigen-binding site. We further explored this relationship through next-generation sequencing and crystallographic analysis of the clonotypic B-cell receptor immunoglobulin. Branching evolution of the predominant clonotype through intraclonal diversification in the context of ongoing SHM was evident in both heavy and light chain genes of both subsets. Molecular similarities between the 2 subsets were highlighted by the finding of shared SHMs within both the heavy and light chain genes in all analyzed cases at either the clonal or subclonal level. Particularly noteworthy in this respect was a ubiquitous SHM at the linker region between the variable and the constant domain of the IGLV3-21 light chains, previously reported as critical for immunoglobulin homotypic interactions underlying cell-autonomous signaling capacity. Notably, crystallographic analysis revealed that the IGLV3-21-bearing CLL subset 169 immunoglobulin retains the same geometry and contact residues for the homotypic intermolecular interaction observed in subset 2, including the SHM at the linker region, and, from a molecular standpoint, belong to a common structural mode of autologous recognition. Collectively, our findings document that stereotyped subsets 2 and 169 are very closely related, displaying shared immunoglobulin features that can be explained only in the context of shared functional selection.

Identifiants

pubmed: 33036024
pii: S0006-4971(21)00777-1
doi: 10.1182/blood.2020005216
doi:

Substances chimiques

Receptors, Antigen, B-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1895-1904

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Katerina Gemenetzi (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.

Fotis Psomopoulos (F)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Alejandra A Carriles (AA)

Biocrystallography Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Maria Gounari (M)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Claudia Minici (C)

Biocrystallography Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Karla Plevova (K)

Hematology and Oncology, Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic.
Faculty of Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.

Lesley-Ann Sutton (LA)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Maria Tsagiopoulou (M)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Panagiotis Baliakas (P)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Kostas Pasentsis (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Achilles Anagnostopoulos (A)

Hematopoietic Cell Transplantation Unit, Department of Hematology, G. Papanikolaou Hospital, Thessaloniki, Greece.

Raphael Sandaltzopoulos (R)

Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.

Richard Rosenquist (R)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.

Frederic Davi (F)

Department of Hematology, Hôpital Pitié-Salpêtrière and Sorbonne University, Paris, France.

Sarka Pospisilova (S)

Hematology and Oncology, Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic.
Faculty of Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.

Paolo Ghia (P)

Medical Oncology, Università Vita-Salute San Raffaele, Milan, Italy; and.
Strategic Research Program on CLL, B Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Massimo Degano (M)

Biocrystallography Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Anastasia Chatzidimitriou (A)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH